Biogen (pharmaceutical company)

Bǎijiàn

百健

for / at (a price)

yǐ

以

$5.6 billion

wǔshíliù yì měiyuán

56亿美元

to acquire

shōugòu

收购

Apellis (pharmaceutical company)

Apellis

Apellis

，

to obtain / to gain

huòdé

获得

eye disease

yǎn bìng

眼病

and

jí

及

kidney disease

shèn bìng

肾病

new treatment / new therapy

xīn liáofǎ

新疗法

。

New Words

News in English

Biogen Acquires Apellis for $5.6 Billion, Adding Treatments for Eye and Kidney Diseases

US pharmaceutical company Biogen announced it will acquire Apellis for $5.6 billion, gaining key drugs for treating eye disease and rare kidney conditions, priced at $41 per share -- a premium of about 140 percent.

U.S. pharmaceutical company Biogen announced it will acquire biotech company Apellis for $5.6 billion.

Apellis operates two promising drug candidates under its umbrella. The company focuses on rare diseases and has demonstrated strong clinical development momentum. This acquisition represents Biogen's strategic expansion into the rare disease treatment segment and demonstrates the company's commitment to diversifying its product portfolio.

Market analysts believe this acquisition will strengthen Biogen's rare disease treatment capabilities and potentially generate significant commercial value. The combined entity will have access to complementary technologies and patient populations, positioning them competitively in the rare disease market.

Industry observers note that acquisitions of biotech companies like Apellis have become increasingly common among major pharmaceutical firms seeking to access innovative therapies and expanding their pipeline of drug candidates.

The transaction is expected to close within the next several months, pending regulatory approval. Biogen's strategy reflects the broader pharmaceutical industry trend of consolidation and innovation-driven growth.

More in Lifestyle & Culture